Structured Support May Slow Weight Regain After GLP-1 Drug Discontinuation

When people stop taking GLP-1 drugs, the weight comes back fast. Studies show that most patients regain at least half of what they lost within a year—a steep and demoralizing reversal that happens because the medication itself, not behavioral change, was doing the work. Researchers wanted to know whether structured support during those critical first months after stopping could slow that rebound. A pilot trial of 39 adults, conducted remotely between March 2024 and August 2025, tested two practical interventions against standard care and found that both slowed early weight regain, though neither stopped it entirely.

The participants were recruited through obesity clinics in Texas and a clinical trial database. All of them had lost more than 10% of their body weight while taking GLP-1 drugs and had stopped treatment within the previous month. On average, they were 50 years old, mostly female (82%), college-educated (69%), and employed (71%). They had achieved an average weight loss of 18% during their time on medication. The researchers divided them into three groups: one received medically tailored meals—10 weight-conscious meals per week delivered to their homes—another got a subscription to Noom, a digital app designed to teach behavioral strategies for weight management, and a third received usual care, meaning whatever their regular healthcare provider recommended with no specific study intervention. The meals and app subscriptions were provided free.

The medically tailored meals were designed to be lower in sodium and saturated fat, with fewer calories and comparable or lower sugar than conventional prepared meals. Participants in the app group were asked to use Noom for at least 15 minutes daily. Over four months, researchers tracked weight using home Bluetooth scales and asked participants to weigh in monthly. They also measured diet quality, perceived health, adherence to the interventions, and satisfaction with the support they received.

Thirty-four of the 39 participants completed the study. Those in the meal group consumed an average of eight meals per week, while those using the app logged in about 2.8 days per week. The weight regain told the story: participants receiving usual care gained approximately 11% of their baseline weight over the four months. Those in both intervention groups—meals and app alike—gained about 3.6%, a difference that held up even after researchers adjusted for how much weight each person had originally lost on medication. No serious adverse events occurred. Interestingly, adherence and satisfaction scores did not differ significantly between the groups, and neither did measures of diet quality or perceived health.

The findings suggest that structured support in the immediate aftermath of stopping GLP-1 therapy can meaningfully slow early weight regain. The difference between 11% and 3.6% is substantial—roughly two-thirds less regain—and it emerged within just four months. Yet the study carries real limitations. The sample was small, the follow-up period was short, and the researchers could not determine whether the benefits persist beyond four months or whether they translate into lasting improvements in cardiometabolic health. The usual care group was heterogeneous, meaning different people received different things from their providers. Some weight measurements were missing, and adherence was self-reported rather than objectively verified. The questionnaire findings about diet quality and health perception did not reach statistical significance, which the researchers attribute to limited statistical power in a pilot study.

What remains unknown is whether these interventions work because they provide structure and accountability, because the meals themselves are nutritionally superior, because the app teaches skills that outlast the intervention, or some combination. Larger, longer trials with more diverse participants and extended follow-up are needed to answer those questions and to determine whether slowing early regain translates into sustained weight maintenance or genuine health gains. For now, the pilot offers a modest but concrete finding: when people stop GLP-1 drugs, giving them structured support—whether meals or behavioral coaching—appears to matter in those first critical months.